Our lawyers share the top investment and regulatory trends from last month’s agenda-setting JP Morgan Health Care Conference. We expect an abundance of novel financing structures, investment focus on new disease states, and important new U.S. Food and Drug Administration (FDA) guidance.

The post Deal Outlook for 2024 Includes GLP-1 Investments, APAC M&A, and More Spinoffs appeared first on GoodLifeSci.